TrialCancer journal (Sudbury, Mass.)

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.